<DOC>
	<DOCNO>NCT02998476</DOCNO>
	<brief_summary>The purpose study assess safety efficacy INCB050465 subject relapse refractory diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>A Phase 2 Safety Efficacy Study INCB050465 Subjects With Relapsed Refractory Diffuse Large B-Cell Lymphoma ( CITADEL-202 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Eligible 19 year old South Korea Relapsed refractory DLBCL , histologically document , define receive least 1 5 prior treatment regimen ineligible highdose chemotherapy support autologous stem cell transplant . Must ≥ 1 measurable lesion ( ≥2 cm long dimension ) ≥ 1 measurable extranodal lesion ( ≥1 cm long dimension ) compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) . Subjects must willing undergo incisional excisional lymph node biopsy accessible adenopathy provide recent , available archived tumor biopsy . Eastern Cooperative Oncology Group performance status 0 2 . Primary mediastinal ( thymic ) large Bcell lymphoma . Known brain central nervous system metastases history uncontrolled seizure . Allogeneic stem cell transplant within last 6 month , active graft versus host disease follow allogeneic transplant , autologous stem cell transplant within last 3 month . Use expect use study prohibit medication , include potent cytochrome P450 3A4 inhibitor inducer within 14 day 5 half life ( whichever longer ) first dose study drug . Prior treatment follow : Group A : Prior treatment selective phosphatidylinositol 3kinase ( PI3K ) δ inhibitor ( eg , idelalisib ) , panPI3K inhibitor , BTK inhibitor ( eg , ibrutinib ) . Group B : Prior treatment selective PI3Kδ inhibitor ( eg , idelalisib ) pan PI3K inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>phosphatidylinositol 3-kinase δ ( PI3Kδ ) inhibitor</keyword>
	<keyword>Bruton 's tyrosine kinase ( BTK )</keyword>
</DOC>